Good Lifestyle

The sudden increase in weight loss drugs has considerably moved the conversation surrounding the loss of books. While it has been shown that there are differences between the best sellers, including What is their effectiveness - They are still notoriously expensive. Naturally, strong competition at the top of the market is starting to affect prices. This includes the new effective weight loss drug Zepbound, which will cost 20% less than Ozempic. Read the rest to find out more about the latest drugs and what his release could mean for potential patients.

In relation: The new drug has people who lose 19% of body weight, according to research - and it is not Ozempic .

The wave of popularity of weight loss drugs has created a little boom in the Number of market options . The last one is Zepbound, a drug known as the shooting produced by the pharmaceutical giant Eli Lilly. It was approved by the U.S. Food & Drug Administration (FDA) on November 8 for Chronic weight management and the treatment of diabetes.

Even if Zepbounde can look like a newcomer, the shooting is already prescribed for patients under the name of Mounjaro. The main difference between the two lies in the last approval: in its current form, Mounjaro is available to treat type 2 diabetes in adults, while Zepbound can be prescribed to overweight patients and who have at least one condition related to Obesity, including high blood pressure, type 2 diabetes or high cholesterol, according to the release of the FDA.

In both cases, weekly shooting injections promote weight loss by introducing a natural hormone in the body known as GLP-1 , helping to reduce and reduce someone's food consumption, according to The New York Times . It is similar to the popular Wegovy obesity medication of the competitor of Novo Nordisk and his drug against diabetes, which is sometimes prescribed outside the loss of weight.

In relation: Popular plan helping people to lose 10 pounds in just 2 weeks .

Although the best weight loss drugs can work in the same way, it seems that the last addition will be different in a significant way. When the FDA approval was announced, Eli Lilly said he would set the Zepbound market price roughly $ 1,060 per month . In comparison, the weight loss drug directly competitor Wegovy costs $ 1,349 per month, according to Fortune .

"We evaluated about 20% lower than that of the GLP-1 obesity medication existing on the market at the time of launch". Anat Ashkénaze , financial director of Eli Lilly, recently said Fortune . "And this is the price of the list. This is not what patients really pay."

According to their insurance coverage, this means that some people may end up paying as little as $ 25 per month for their Zepbound prescription. And if their plan does not include weight loss drugs, patients may still be eligible for a company's assistance program which lowers the cost from 50% to $ 550 per month, Fortune reports.

In relation: The ozempic patient reveals "a new" atrocious "side effect .

In addition to providing another option for potential patients, Zepbound's approval and lower prices could help open the way to easier access weight loss drugs. Eli Lilly's leadership resolved it directly, saying that he had spoken with employers of the cost before his release to determine how he could work in insurance plans.

"They said that the price of the list was something that was a factor in their decision to extend access to people who need these drugs," Mike Mason , president of Lilly Diabetes and Obesity Division, told journalists on November 8, according to CNN. AE0FCC31AE342FD3A1346EBB1F342FCB

The drug itself could also be more efficient that its more expensive competitor.

"The shooting is in a whole new class of drugs. It is a combined peptide. This double agonist approach seems to cause Zepbound or Mounjaro injections to lose even more weight than those who use a drug that only acts a hormonal path" , " Cecilia Low Wang , MD, an endocrinologist and an expert in diabetes and metabolism, told Uchealth, noting that Ozempic and Wegovy use a single peptide.

In relation: Weightwatchers apologizes to customers while pivoting weight loss drugs: "We were wrong" .

However, there are still many factors at stake that could prevent Zepbound from reducing prices. Continuous shortages of weight loss drugs have created a crunch For patients who rely on them for health reasons. This could potentially pin the market as People pay For drugs sought.

"We do not expect any price war when demand considerably exceeds supply", " David Risinger , told Business Insider, principal director of investment investment, told Business Insider.

But Zepbound's final "net" "net" price will come down to talks between insurance companies and pharmaceutical intermediaries to determine what people pay, according to Business Insider. In comparison, Wegovy's net price is currently about half of its list price. And because of the market conditions, some believe that costs could eventually descend.

"The net price will always be a negotiation", " Craig Garthwaite , PHD, an economist at Northwestern University, told Business Insider. "I imagine it ends or slightly below what you will see for Wegovy because they are in a price war now."

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.

In relation: For more information, register for our daily newsletter .